Filing Flows › Anika Therapeutics (ANIK) › Recalls, complaints & regulation
Anika Therapeutics (ANIK): clinical trials
Anika Therapeutics (ANIK) beyond its filings: 2 active clinical trials.
Anika Therapeutics' latest quarter
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Anika Therapeutics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.